You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The alliance, led by Singapore-based startup Proteona, also includes several organizations from that city state as well as German research institutes.
Chipscreen is developing a small molecule inhibitor of key serine-threonine kinases involved in tumor angiogenesis, cell mitosis, and microenvironment inflammation.
The partnership brings Mission Bio's Tapestri NGS-based single-cell sequencing platform for cancer profiling to the Chinese market.
A brief recap of Genetics/Genomics news the week of Mar 22, 2019: Novogene, Hologic, Agilent, and Diagenode
Novogene's Chinese clinical lab will offer LifeMap's recently updated TGex next-generation sequencing data analysis and interpretation platform.
The firm's next-generation sequencing diagnostic test analyzes tumor samples from multiple genomic mutations that are targeted by therapies for non-small cell lung cancer.
The partners will develop next-generation sequencing-based tests for precision cancer treatment for the Asian market.
Researchers identified trait-related variants by sequencing more than 400 upland cotton accessions and nearly 250 representatives from two diploid Gossypium species.
The lab is located within Novogene's sequencing center at the Sacramento campus of the University of California, Davis.
The Chinese government has implemented clearer regulatory guidance for genomic tests and invested in both clinical testing and research, spurring growth.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.